Drug Combination Details
| General Information of the Combination (ID: C23725) | |||||
|---|---|---|---|---|---|
| Name | 17-beta-Estradiol NP Info | + | Methotrexate Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | MDA-MB-436 | CVCL_0623 | Invasive breast carcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
17-beta-oestradiol partially reversed the anti-proliferative effects of MTX in the MDA-MB-436 line and potentiated growth inhibition in the E2 responsive cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Oestrogen receptor status and the response of human breast cancer cell lines to a combination of methotrexate and 17-beta oestradiol. Br J Cancer. 1985 Mar;51(3):365-9. | |||
